齐鲁制药旗下申可安在阿里健康首发为“剂末现象”帕金森病患者提供新选择

动脉网2025-12-23

12月22日，齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)（申可安）在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。我国65岁以上人群帕金森病患病率约1.7%，患者总数超300万，长期接受左旋多巴治疗的患者易出现“剂末现象”，严重影响生活质量。申可安整合三种成分制成单一复方片剂，可提高左旋多巴入脑水平，延长其半衰期，减轻外周不良反应，简化用药...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593414568?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 09:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2593414568","market":"hk","top_or_hot":-1,"title":"齐鲁制药旗下申可安在阿里健康首发为“剂末现象”帕金森病患者提供新选择","media":"动脉网","content":"<div>\n<p>12月22日，齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)（申可安）在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。我国65岁以上人群帕金森病患病率约1.7%，患者总数超300万，长期接受左旋多巴治疗的患者易出现“剂末现象”，严重影响生活质量。申可安整合三种成分制成单一复方片剂，可提高左旋多巴入脑水平，延长其半衰期，减轻外周不良反应，简化用药...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>齐鲁制药旗下申可安在阿里健康首发为“剂末现象”帕金森病患者提供新选择</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n齐鲁制药旗下申可安在阿里健康首发为“剂末现象”帕金森病患者提供新选择\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 09:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月22日，齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)（申可安）在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。我国65岁以上人群帕金森病患病率约1.7%，患者总数超300万，长期接受左旋多巴治疗的患者易出现“剂末现象”，严重影响生活质量。申可安整合三种成分制成单一复方片剂，可提高左旋多巴入脑水平，延长其半衰期，减轻外周不良反应，简化用药...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1501","symbol_name":"阿里概念股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b","article_id":"2593414568","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223100739a6c3bc63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593414568","pubTimestamp":1766454720,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月22日，齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)（申可安）在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。申可安整合三种成分制成单一复方片剂，可提高左旋多巴入脑水平，延长其半衰期，减轻外周不良反应，简化用药方案，提升患者依从性。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1501":"阿里概念股","BK1610":"ETF&股票定投概念","00241":"阿里健康","BK1191":"制药","BK1574":"生物医药B类股","BK1591":"就地过年概念","BK1142":"互联网与直销零售","BK1615":"港股-互联网","BK1189":"医疗保健技术","BK1247":"药品零售","BK1584":"蚂蚁金服概念","BK1502":"双十一","01477":"欧康维视生物-B","BK1617":"AI医疗","BK1571":"互联网医疗","BK1589":"北水核心资产","BK1515":"抗疫概念"},"translate_title":"Shenkean, a subsidiary of Qilu Pharmaceutical, launched on Alibaba Health to provide new options for Parkinson's disease patients with \"end-of-dose phenomenon\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1.5,"00241":1.5},"content_text":"12月22日，齐鲁制药旗下恩他卡朋双多巴片(Ⅱ)（申可安）在阿里健康首发。该药适用于治疗经左旋多巴/多巴脱羧酶抑制剂疗法未能控制的“剂末”运动功能波动的成人帕金森病患者。我国65岁以上人群帕金森病患病率约1.7%，患者总数超300万，长期接受左旋多巴治疗的患者易出现“剂末现象”，严重影响生活质量。申可安整合三种成分制成单一复方片剂，可提高左旋多巴入脑水平，延长其半衰期，减轻外周不良反应，简化用药方案，提升患者依从性。申可安获批是齐鲁制药在中枢神经治疗领域的重要进展，也是其今年获批的第22个新产品。阿里健康作为首发渠道，提供医学科普、药师服务与便捷购药配送，还通过数字化工具构建线上管理闭环，提升患者生活质量。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593414568","isCrawlerRequest":true}